Aurinia Pharmaceuticals (IKAP) Ratios
1 Followers
Aurinia Pharmaceuticals Ratios
DE:IKAP's free cash flow for Q3 2026 was $46.34M. For the 2026 fiscal year, DE:IKAP's free cash flow was decreased by $-24.00K and operating cash flow was $46.37M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 |
| Quick Ratio | 4.76 | 4.17 | 4.99 | 9.06 | 12.15 |
| Cash Ratio | 0.86 | 0.85 | 0.63 | 2.04 | 5.71 |
| Solvency Ratio | 1.74 | 0.15 | -0.39 | -1.61 | -2.77 |
| Operating Cash Flow Ratio | 1.45 | 0.45 | -0.43 | -1.72 | -3.88 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 321.71M | $ 273.43M | $ 254.69M | $ 377.11M | $ 449.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.14 | 0.18 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.13 | 0.21 | 0.26 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.11 | 0.17 | 0.21 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.46 | 1.45 | 1.16 | 1.13 |
| Debt Service Coverage Ratio | 69.47 | 6.21 | -22.92 | 0.00 | 0.00 |
| Interest Coverage Ratio | 24.23 | -0.97 | -33.04 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.59 | 0.59 | 0.70 | 0.06 | 0.07 |
| Net Debt to EBITDA | -0.04 | -0.13 | -0.77 | 0.83 | 1.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 88.46% | 87.99% | 91.94% | 95.77% | 97.61% |
| EBIT Margin | 41.86% | 5.22% | -42.56% | -79.35% | -395.15% |
| EBITDA Margin | 45.14% | 13.49% | -35.92% | -77.33% | -389.09% |
| Operating Profit Margin | 37.06% | -1.99% | -52.24% | -83.17% | -396.31% |
| Pretax Profit Margin | 40.33% | 3.17% | -44.14% | -79.35% | -395.15% |
| Net Profit Margin | 101.47% | 2.45% | -44.45% | -80.71% | -396.81% |
| Continuous Operations Profit Margin | 101.47% | 2.45% | -44.45% | -80.71% | -396.81% |
| Net Income Per EBT | 251.59% | 77.23% | 100.71% | 101.72% | 100.42% |
| EBT Per EBIT | 108.81% | -158.91% | 84.49% | 95.41% | 99.71% |
| Return on Assets (ROA) | 38.21% | 1.04% | -14.24% | -22.97% | -33.30% |
| Return on Equity (ROE) | 49.40% | 1.52% | -20.64% | -26.68% | -37.77% |
| Return on Capital Employed (ROCE) | 15.95% | -1.03% | -19.47% | -26.24% | -35.95% |
| Return on Invested Capital (ROIC) | 15.53% | -0.77% | -18.85% | -26.19% | -35.88% |
| Return on Tangible Assets | 38.40% | 1.05% | -14.37% | -23.29% | -33.83% |
| Earnings Yield | 13.40% | 0.45% | -6.06% | -17.65% | -6.12% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.83 | 6.43 | 7.29 | 9.94 | 2.96 |
| Payables Turnover | 9.86 | 5.45 | 3.27 | 1.83 | 0.28 |
| Inventory Turnover | 0.71 | 0.72 | 0.36 | 0.23 | 0.06 |
| Fixed Asset Turnover | 3.56 | 2.38 | 1.51 | 15.66 | 4.65 |
| Asset Turnover | 0.38 | 0.43 | 0.32 | 0.28 | 0.08 |
| Working Capital Turnover Ratio | 0.76 | 0.68 | 0.47 | 0.31 | 0.11 |
| Cash Conversion Cycle | 526.98 | 496.58 | 962.80 | 1432.86 | 5291.24 |
| Days of Sales Outstanding | 53.46 | 56.73 | 50.10 | 36.72 | 123.37 |
| Days of Inventory Outstanding | 510.54 | 506.88 | 1024.34 | 1595.07 | 6465.62 |
| Days of Payables Outstanding | 37.02 | 67.02 | 111.63 | 198.93 | 1297.74 |
| Operating Cycle | 564.00 | 563.60 | 1074.43 | 1631.79 | 6588.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.01 | 0.31 | -0.23 | -0.56 | -1.22 |
| Free Cash Flow Per Share | 1.01 | 0.31 | -0.24 | -0.56 | -1.23 |
| Dividend Paid and CapEx Coverage Ratio | 538.33 | 157.96 | -46.60 | -272.36 | -105.06 |
| Capital Expenditure Coverage Ratio | 538.33 | 157.96 | -46.60 | -272.36 | -105.06 |
| Operating Cash Flow Coverage Ratio | 1.81 | 0.56 | -0.34 | -9.83 | -18.04 |
| Operating Cash Flow to Sales Ratio | 0.48 | 0.19 | -0.19 | -0.59 | -3.46 |
| Free Cash Flow Yield | 6.32% | 3.43% | -2.65% | -13.02% | -5.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7.45 | 224.50 | -16.50 | -5.67 | -16.35 |
| Price-to-Sales (P/S) Ratio | 7.57 | 5.46 | 7.34 | 4.57 | 64.88 |
| Price-to-Book (P/B) Ratio | 3.69 | 3.40 | 3.41 | 1.51 | 6.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 15.83 | 29.13 | -37.67 | -7.68 | -18.59 |
| Price-to-Operating Cash Flow Ratio | 15.80 | 28.94 | -38.48 | -7.71 | -18.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -2.09 | 0.57 | 0.12 | -0.27 |
| Enterprise Value Multiple | 16.73 | 40.36 | -21.20 | -5.08 | -15.42 |
| Enterprise Value | 2.14B | 1.28B | 1.34B | 526.99M | 2.74B |
| EV to EBITDA | 16.73 | 40.36 | -21.20 | -5.08 | -15.42 |
| EV to Sales | 7.55 | 5.45 | 7.61 | 3.93 | 59.98 |
| EV to Free Cash Flow | 15.79 | 29.03 | -39.10 | -6.60 | -17.18 |
| EV to Operating Cash Flow | 15.76 | 28.85 | -39.94 | -6.63 | -17.35 |
| Tangible Book Value Per Share | 4.30 | 2.61 | 2.60 | 2.81 | 3.64 |
| Shareholders’ Equity Per Share | 4.33 | 2.64 | 2.64 | 2.86 | 3.70 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -1.52 | 0.23 | -0.01 | -0.02 | -0.00 |
| Revenue Per Share | 2.11 | 1.64 | 1.23 | 0.94 | 0.35 |
| Net Income Per Share | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 |
| Tax Burden | 2.52 | 0.77 | 1.01 | 1.02 | 1.00 |
| Interest Burden | 0.96 | 0.61 | 1.04 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.11 | 0.09 | 0.28 | 0.34 | 1.12 |
| SG&A to Revenue | 0.36 | 0.73 | 1.11 | 1.47 | 3.76 |
| Stock-Based Compensation to Revenue | 0.05 | 0.13 | 0.26 | 0.24 | 0.69 |
| Income Quality | 0.47 | 7.72 | 0.43 | 0.74 | 0.87 |
Currency in USD
